8 August 2024 in Journal of Clinical Investigation
Obesity is linked to an increased risk of atrial fibrillation (AF) via increased oxidative stress. While NADPH oxidase 2 (NOX2), a major source of oxidative stress and reactive oxygen species (ROS) in the heart, predisposes to AF, the underlying mechanisms remain unclear. Here, we studied NOX2-mediated ROS production in obesity-mediated AF using Nox2 -knockout mice and mature human induced pluripotent stem cell–derived atrial cardiomyocytes (hiPSC-aCMs). Diet-induced obesity (DIO) mice and hiPSC-aCMs treated with palmitic acid (PA) were infused with a NOX blocker (apocynin) and a NOX2-specific inhibitor, respectively. We showed that NOX2 inhibition normalized atrial action potential duration and abrogated obesity-mediated ion channel remodeling with reduced AF burden. Unbiased transcriptomics analysis revealed that NOX2 mediates atrial remodeling in obesity-mediated AF in DIO mice, PA-treated hiPSC-aCMs, and human atrial tissue from obese individuals by upregulation of paired-like homeodomain transcription factor 2 (PITX2). Furthermore, hiPSC-aCMs treated with hydrogen peroxide, a NOX2 surrogate, displayed increased PITX2 expression, establishing a mechanistic link between increased NOX2-mediated ROS production and modulation of PITX2. Our findings offer insights into possible mechanisms through which obesity triggers AF and support NOX2 inhibition as a potential novel prophylactic or adjunctive therapy for patients with obesity-mediated AF.
28 February 2024 in JACC: Basic To Translational Science
• The diversity of genes and biological pathways involved in AF pathogenesis and variability in individual response to treatment highlights the need for a personalized approach for AF management. Over the past decade, GWAS have identified more than 140 AF-associated loci, and family-based studies have identified rare variants in genes encoding ion channel as well as non–ion channel proteins. • This review discusses studies that have provided novel insights regarding variant-specific pathophysiologic mechanisms that can pave the way for personalized medicine for AF. • Recent translational advances in AF genetics include the development of high-throughput in vitro assays for functional validation of variants of uncertain significance that can bridge the gap in variant classification and risk stratification. • GWAS-derived PRS for AF can be used for predicting AF risk and adverse outcomes. Further studies are needed to validate if AF PRS are superior to traditional risk stratification tools. • Genotype-guided clinical trials and advances in bioengineered preclinical models are needed for developing personalized therapy for AF.
25 April 2021 in Experimental Biology and Medicine
Induced pluripotent stem cells (iPSCs) serve as a robust platform to model several human arrhythmia syndromes including atrial fibrillation (AF). However, the structural, molecular, functional, and electrophysiological parameters of patient-specific iPSC-derived atrial cardiomyocytes (iPSC-aCMs) do not fully recapitulate the mature phenotype of their human adult counterparts. The use of physiologically inspired microenvironmental cues, such as postnatal factors, metabolic conditioning, extracellular matrix (ECM) modulation, electrical and mechanical stimulation, co-culture with non-parenchymal cells, and 3D culture techniques can help mimic natural atrial development and induce a more mature adult phenotype in iPSC-aCMs. Such advances will not only elucidate the underlying pathophysiological mechanisms of AF, but also identify and assess novel mechanism-based therapies towards supporting a more ‘personalized’ (i.e. patient-specific) approach to pharmacologic therapy of AF.